ViSci Visual Sciences Ltd.

Vi-Sci’s innovative Eye-D technology treats glaucoma by the insertion of a sub-conjunctival implant, which releases the prescribed medication “Latanaprost”, in sustained release manner, eliminating the need to use eye drops, a daily challenge for the aged. The implant; an in-office medical procedure is developed by ViSci, branded as VS-101, is licensed for global use and is in its development phase. ViSci’s Market The global glaucoma drug market is expected to cross the $10 billion mark by 2026, with the most significant growth expected in developing countries and areas such as China, India and South America. Glaucoma is the most prominent global cause of irreversible blindness while patients’ levels of persistence with recommended and effective drug treatment are unusually low. Many companies are seeking a solution that will reduce patients’ treatment burden without impacting the efficacy of the treatment and without raising the level of risk associated with treatment, yet maintaining economic logic for insurers and healthcare systems. The solutions developed by ViSci reduce the burden of treatment for glaucoma patients by placing an implant under the conjunctiva in the clinic, in a simple and short procedure, by a dedicated implanter developed by the company. ViSci is actively seeking a financing partner for the next clinical trial required in the development process. ViSci is a subsidiary of BioLight Life Sciences with Yaaecov Michlin, CEO of BioLIght serving as its Chairman.